Orforglipron | Drug interactions | Litt's Drug Eruption and Reaction Database

Orforglipron comment watch save

TRADE NAMES: Foundayo (Eli Lilly and Co); LY3502970 (Eli Lilly and Co)
INDICATIONS:
Reduction of excess body weight and the long-term maintenance of a reduced body weight in adults who have at least one weight-related comorbid condition.
CLASS: Anti-obesity / weight loss pharmacotherapy, Glucagon-like peptide-1 (GLP-1) receptor agonist
HALF-LIFE: Approx. 29–49 hours

FDA APPROVAL DATE: 04/01/2026
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atorvastatin, Carbamazepine, Clarithromycin, Cyclosporine, CYP3A4 inducers, CYP3A4 inhibitors, Digoxin, Efavirenz, Esomeprazole, Insulin or insulin secretagogue, Midazolam, Modafinil, Quinidine, Rosuvastatin, Simvastatin, Verapamil
PREGNANCY: May cause fetal harm. When pregnancy is recognized, discontinue orforglipron. Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation and for 30 days after each dose escalation.

See adverse reactions attributed to class:
Anti-obesity / weight loss pharmacotherapy
Glucagon-like peptide-1 (GLP-1) receptor agonist

Not recommended for use in patients with severe hepatic impairment.

Orforglipron delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.

Orforglipron is administered as a calcium salt.

WARNING: RISK OF THYROID C-CELL TUMORS

IN PRODUCTS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST ACTIVITY THAT ARE PHARMACOLOGICALLY ACTIVE IN RATS AND MICE, RODENT THYROID C-CELL TUMORS (ADENOMAS AND CARCINOMAS) HAVE BEEN OBSERVED AT CLINICALLY RELEVANT EXPOSURES AND ARE CONSIDERED GLP-1 RECEPTOR-DEPENDENT EFFECTS IN RODENTS.

ORFORGLIPRON IS NOT PHARMACOLOGICALLY ACTIVE IN RATS OR MICE AND DID NOT PRODUCE TUMORS IN RODENTS. WHILE ORFORGLIPRON IS PHARMACOLOGICALLY ACTIVE AT THE HUMAN GLP-1 RECEPTOR, THE HUMAN RELEVANCE OF GLP-1 RECEPTOR-DEPENDENT THYROID C-CELL TUMORS OBSERVED IN RODENTS HAS NOT BEEN DETERMINED.

ORFORGLIPRON IS CONTRAINDICATED IN PATIENTS WITH A PERSONAL OR FAMILY HISTORY OF MEDULLARY THYROID CARCINOMA OR IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA SYNDROME TYPE 2. COUNSEL PATIENTS REGARDING THE POTENTIAL RISK OF MEDULLARY THYROID CARCINOMA AND SYMPTOMS OF THYROID TUMORS.

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 05/15/2026

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

Breast feeding

Geriatric

Pediatric